https://orcid.org/0000-0001-7876-5802
Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
William L. Baker, Matthew S. Roberts, Youssef Bessada, Kimberly S. Caroti, Veronica Ashton, Brahim K. Bookhart & Craig I. Coleman. (2023) Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies. Current Medical Research and Opinion 39:9, pages 1183-1194.
Read now
Read now
Yinong Young-Xu, Richard Melsheimer, Bruno Emond, Patrick Lefebvre, Maral DerSarkissian, Angela Lax, Catherine Nguyen, Rachel H. Bhak, Melody Wu & Iris Lin. (2022) Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627. Current Medical Research and Opinion 38:12, pages 2237-2240.
Read now
Read now
Knut Stavem. (2021) Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief review. Journal of Market Access & Health Policy 9:1.
Read now
Read now
Articles from other publishers (4)
Puneet Kaur ChehalElizabeth SelvinJennifer E. DeVoeCarol M. MangioneMohammed K. Ali. (2022) Diabetes And The Fragmented State Of US Health Care And Policy. Health Affairs 41:7, pages 939-946.
Crossref
Crossref
Gwenneth Feeny, Irene O. Aninye, Kelly Barta, Stacie Bell, Thea Chassin, Eunyoung Cho, Shawn G. Kwatra, Brett McReynolds, Arash Mostaghimi, Purvi Parikh, Rita O. Pichardo & Leslie Stein Lloyd. (2022) Addressing Autoimmune and Immune-mediated Skin Disease Burden in Women. Women's Health Issues 32:4, pages 322-326.
Crossref
Crossref
Steven KheloussiAlicia JohnsVincenzo ParenteWilliam McLayMichael R Gionfriddo. (2021) Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes. Journal of Managed Care & Specialty Pharmacy 27:7, pages 846-854.
Crossref
Crossref
Cosimo Bruni, Stefano Gentileschi, Giovanni Pacini, Caterina Baldi, Marco Capassoni, Lorenzo Tofani, Marco Bardelli, Laura Cometi, Luca Cantarini, Francesca Nacci, Michele Vietri, Francesca Bartoli, Ginevra Fiori, Bruno Frediani & Marco Matucci-Cerinic. (2020) The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2096403.
Crossref
Crossref